Dr. Nagle on Investigational Cellular Therapies in Multiple Myeloma

Video

Sarah Nagle, MD, assistant professor of medicine, School of Medicine, Oregon Health & Science University, discusses investigational cellular therapies in multiple myeloma.

Sarah Nagle, MD, assistant professor of medicine, School of Medicine, Oregon Health & Science University, discusses investigational cellular therapies in multiple myeloma.

There are several emerging cellular therapies in the multiple myeloma space, which are expected to receive regulatory approval within the next year. The first is idecabtagene vicleucel (ide-cel; bb2121), which targets BCMA, Nagle says.

Next, there is JNJ-4528, an investigational, BCMA-directed CAR T-cell product which is currently being evaluated in the CARTITUDE-1 study for the treatment of patients with relapsed/refractory multiple myeloma. This product has shown very encouraging results thus far, Nagle says.

Notably, despite the host of BCMA-targeted agents that are currently under exploration, there is an increasing interest in discovering new targets, especially for patients who relapse after BCMA-directed therapies, Nagle concludes.

Related Videos
Emmanuel Antonarakis, MD, associate director, Translational Research, Masonic Cancer Center, University of Minnesota, Clark Endowed Professor of Medicine, University of Minnesota Medical School
Gautam Jha, MD, medical director, M Health Fairview Masonic Cancer Clinic and the Advanced Treatment Center at the M Health Fairview Clinics and Surgery Center—Minneapolis, chair, cancer committee, M Health Fairview Ridges Hospital
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Corey Cutler, MD, MPH, and Hana Safah, MD, experts on GvHD